Effects of celecoxib on tumor growth and cell apoptosis in human triple-negative breast cancer xenografts in nude mice
10.3760/cma.j.issn.1006-9801.2011.11.006
- VernacularTitle:塞来昔布抑制人类三阴性乳腺癌裸鼠移植瘤生长的实验研究
- Author:
Ling WANG
;
Baoen SHAN
;
Lihong LIU
;
Jie LI
;
Bin WANG
- Publication Type:Journal Article
- Keywords:
Celecoxib;
Breast neoplasms;
Apoptosis;
NF-κB;
Animal experimentation
- From:
Cancer Research and Clinic
2011;23(11):739-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of celecoxib on tumor growth and cell apoptosis in human triple-negative breast cancer (TNBC) xenografts in nude mice.Methods Human TNBC MDA-MB-231 cells were inoculated subcutaneously into BALB/c nude mice.The mice (n=32) were then randomly divided into 4 groups,the control group and the celecoxib group (receiving 25,50,100 mg·kg-1·d-1 respectively).At the end of the study,tumor tissues were collected and tumor volume was measured.Cell apoptosis was determined by flow cytometry (FCM) analysis.NF-κB p65 and pS0 protein levels were measured by immunohistochemistry.Caspase-3 and survivin protein levels were detected by western blotting.Results celecoxib at dose of 25,50 and 100 mg·kg-1·d-1 inhibited the tumor growth significantly,compared with the control group.FCM results showed that apoptotic rates were (13.58±3.16) % and (21.91±4.75) % in moderate and high dose of celecoxib-treated group,compared with (3.15±1.73) % in control group (t =6.736,P < 0.05;t =12.151,P < 0.05).p65 expressions were 79.3 %,46.7 % and 23.9 % in low,moderate and high dose of celecoxib-treated group,compared with 89.7 % in control group (x2 =3.312,P < 0.05; x2 =10.785,P < 0.05;x2 =15.900,P < 0.05).Besides,western blotting analysis demonstrated that celecoxib significantly downregulated survivin expression,while upregulated the active form of caspase-3 expression.Conclusion Celecoxib could suppress TNBC tumor growth and induce cell apoptosis,which might be partially associated with inactivation of p65 and downregulation of survivin.